A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence

Medina‐Catalán, David; Riera, Pau; Pagès-Puigdemont, Neus; Masip, Montserrat; López‐Ferrer, Anna; Vilarrasa, Eva; Puig, Lluís

doi:10.1007/s11096-022-01400-z

Cited by 7 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in VOYAGE 1, PASI 75 and PASI 90 were 76.3% and 87.8%, respectively, at 48 weeks. Similar outcomes were obtained in our study, where 88% of patients Our findings are also consistent with other real-life guselkumab studies [12,[15][16][17][18][19]. For example, an Italian study that had a mean ± SD baseline PASI score of 15.1 ± 6.1 showed that PASI 75, 90, and 100 were achieved by 95.6%, 73.9%, and 43.5% of patients at 44 weeks, respectively Likewise, our study achieved PASI 75, 90, and 100 in 88%, 72%, and 48% of patients at 52 weeks, respectively.…”

Section: Discussionsupporting

confidence: 93%

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Yang

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Yang

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“… 33 At the first follow-up visit (25.6 ± 11.5 weeks), 19 patients (55.9%) reached PASI 100, 24 (70.6%) reached PASI 90, and 32 (94.1%) reached PASI 75. 33 As for safety, 3 (8.6%) patients developed AE due to guselkumab. One patient showed paradoxical psoriasis attributable to guselkumab after the first dose and treatment was interrupted (2.9%).…”

Section: Methodsmentioning

confidence: 92%

“…All patients had previously received at least one biologic treatment, such as anti-TNF-alpha, anti-IL-17, and anti-IL-12/23 agents, with a median of 2 biologic drugs per patient. 33 At the first follow-up visit (25.6 ± 11.5 weeks), 19 patients (55.9%) reached PASI 100, 24 (70.6%) reached PASI 90, and 32 (94.1%) reached PASI 75. 33 As for safety, 3 (8.6%) patients developed AE due to guselkumab.…”

Section: Methodsmentioning

confidence: 92%

“… 32 A retrospective real-life study was conducted evaluating all patients with moderate-to-severe psoriasis who started treatment with guselkumab at Hospital de la Santa Creu i Sant Pau, Barcelona (Spain), between February 2019 and October 2020. 33 A total of 35 patients were included in the study. All patients had previously received at least one biologic treatment, such as anti-TNF-alpha, anti-IL-17, and anti-IL-12/23 agents, with a median of 2 biologic drugs per patient.…”

Section: Methodsmentioning

confidence: 99%

“…None of the other patients reported side effects during the follow-up period. 33 In a 52-week real-life retrospective longitudinal study 52 patients with moderate-to-severe plaque psoriasis were treated with guselkumab and followed for 12 months, demonstrating at 12 weeks a PASI 75, 90, and 100 response of 68%, 36%, and 18% of patients, respectively. 34 After 1 year, PASI 75, 90, and 100 response was reached in 84.2%, 78.9%, and 63.2% of patients, respectively.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Ruggiero¹,

Picone²,

Fabbrocini³

et al. 2022

CCID

View full text Add to dashboard Cite

Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL-23 use in routine clinical practice. Indeed, real-life data are important to improve the dermatological decision-making process, including patients who are typically excluded from clinical trials, such as subjects suffering from several comorbidities, subjects on polypharmacy, as well as multifailure patients. Herein, we performed a comprehensive literature review about real-life data available on guselkumab, risankizumab, and tildrakizumab. Real-life data of anti-IL-23 seem to confirm the promising results of IL-23 shown by clinical trials, highlighting the efficacy and safety profiles of this new class of biologics also in clinical practice.

show abstract

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

The approved biologics targeting interleukin (IL)-23 p19 for the treatment of moderate-to-severe plaque psoriasis, including guselkumab, tildrakizumab, and risankizumab, have generally favorable safety profiles. The aim of the current review is to describe in detail the safety of these selective inhibitors. A literature search was performed using PubMed from inception to 1 November 2022, to identify clinical trials and real-world evidence publications using the keywords “guselkumab,” “tildrakizumab,” and “risankizumab.” Overall, the most common adverse events (AEs) associated with IL-23 p19 inhibitors in clinical trials were nasopharyngitis, headache, and upper respiratory tract infections. Rates of serious AEs and AEs of interest, including serious infections, nonmelanoma skin cancer (NMSC), malignancies excluding NMSC, major adverse cardiovascular events, and serious hypersensitivity reactions, were not increased with long-term use in clinical trials. Selectively targeting IL-23 p19 was also not associated with elevated risk of opportunistic infections, tuberculosis reactivation, oral candidiasis, or inflammatory bowel disease. Results from real-world studies were similar, supporting the safe long-term use of these biologics in a wider population of patients with psoriasis, including older patients, patients for whom multiple biologics failed, and those with comorbidities such as obesity, metabolic syndrome, cardiovascular disease, dyslipidemia, diabetes, hypertension, and psoriatic arthritis. This review is limited by the lack of direct comparisons among therapeutic agents due to differences among study designs and safety data reporting methods. In conclusion, the favorable safety profiles of IL-23 p19 inhibitors support their long-term use in the management of patients with moderate-to-severe psoriasis.

show abstract

A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence

Cited by 7 publications

References 24 publications

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review

Contact Info

Product

Resources

About